News

Layne Los, PhD, CEO of ClaroLabs announced the company has raised $800K in the first round of a $2M Series A preferred stock offering

Layne Los, PhD, CEO of ClaroLabs announced the company has raised $800K in the first round of a $2M Series A preferred stock offering. The company recently setup operations in a 5000+ sq. ft. facility in Lafayette, CO. Claro Scientific Laboratories, Inc is a clinical reference Lab (CLIA) providing urine drug testing services for Addiction Recovery Clinics, Pain Clinics and a Direct to Consumer service.

For people with Substance Use Disorder (SUD, diagnosed or not) knowing unequivocally if a loved one is using is one of the first steps in the recovery process. Unlike other less sophisticated tests, our service detects 152 drugs, many days if not weeks, after drug use (depending on the drug and dose). ClaroLabs will be accepting samples in January 2018.

For more information and to order a test kit, visit clarolabs.com.





Go Back